Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 2,882,050 | 6,457,645 | 8,215,093 | 6,274,385 | 8,620,366 | 32,449,539 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 2,882,050 | 6,457,645 | 8,215,093 | 6,274,385 | 8,620,366 | 32,449,539 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 0 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 32,449,539 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 2,882,050 | 6,457,645 | 8,215,093 | 6,274,385 | 8,620,366 | 32,449,539 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 505 | 11,021 | 203,264 | 386,556 | 320,297 | 921,643 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 301 | 777 | 2,749 | 921 | 1,853 | 6,601 |
| 11 | Total support. Add lines 7 through 10 | 33,377,783 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2024 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2024 |
(iii) Distributable Amount for 2024 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2024 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2024 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2024: | ||||
| a From 2019....... | ||||
| b From 2020....... | ||||
| c From 2021....... | ||||
| d From 2022....... | ||||
| e From 2023....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2024 distributable amount | ||||
|
i
Carryover from 2019 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2024 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2024 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2024, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2024. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2025. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2020..... | ||||
| b Excess from 2021..... | ||||
| c Excess from 2022..... | ||||
| d Excess from 2023..... | ||||
| e Excess from 2024..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 4A | THE FOOD ALLERGY SCIENCE INITIATIVE ("FASI") WAS FOUNDED IN 2016 BY A GROUP OF PARENTS UNITED THROUGH A SHARED EXPERIENCE THAT NO PARENT SHOULD HAVE TO GO THROUGH: WITNESSING THEIR CHILD EXPERIENCE A LIFE-THREATENING ALLERGIC REACTION. FRUSTRATED BY THE LACK OF OPTIONS TO TREAT FOOD ALLERGIES, THEY IDENTIFIED A FUNDAMENTAL ISSUE: DESPITE MANY DECADES OF RESEARCH INTO THE IMMUNE SYSTEM AND ADVANCES IN CLINICAL MEDICINE, SHOCKINGLY LITTLE IS KNOWN ABOUT THE FUNDAMENTAL BIOLOGY BEHIND THE CAUSE AND PATHOLOGICAL DRIVERS OF FOOD ALLERGIES. IMPORTANTLY, WHAT HAPPENS WHEN AN INDIVIDUAL FIRST BECOMES SENSITIZED TO AN ALLERGEN? WHY ARE CERTAIN FOODS MORE LIKELY TO BE ALLERGENIC? WHY DO SOME PEOPLE REACT MORE VIGOROUSLY TO ALLERGENS, OR NATURALLY OUTGROW SOME FOOD ALLERGIES, OR RESPOND DIFFERENTLY TO TREAMENTS, WHILE OTHERS DO NOT? WHAT CHANGES MIGHT BE HAPPENING IN OUR ENVIRONMENTS AND OUR EXPOSURES THAT ARE CONTRIBUTING TO THE PROLIFIC RISE IN FOOD ALLERGIES? BY RECOGNIZING THAT A COMPREHENSIVE UNDERSTANDING OF THE MULTIPLE AND COMPLEX MECHANISMS UNDERLYING FOOD ALLERGY PATHOLOGY CANNOT BE ACHIEVED BY MYOPIC RESEARCH, THE FOUNDERS OF FASI WERE DRIVEN TO ORGANIZE A LANDMARK SYMPOSIUM IN 2015 THAT BROUGHT TOGETHER WORLD-CLASS EXPERTS FROM MULTIPLE DISCIPLINES OF SCIENCE TO DISCUSS HOW THEIR RESEARCH SHEDS LIGHT ON THIS ENORMOUSLY COMPLEX PROBLEM AND HOW THEIR RESEARCH COULD SYNERGIZE TO MAKE INROADS IN DEVELOPING A MUCH NEEDED CURE. THUS, IN 2016 FASI WAS LAUNCHED WITH THE BROAD INSTITUTE OF MIT AND HARVARD (THE "BROAD"). WITH JUST SIX LABS AT INCEPTION, FASI HAS GROWN AND EVOLVED INTO AN INDEPENDENT 501(C)(3) MULTI-FACETED NON-PROFIT RESEARCH ORGANIZATION, AND AS OF JUNE 2024, OPERATES WITH MORE THAN 20 WORLD-CLASS LABS AND OVER 100+ SCIENTISTS ACROSS THE UNITED STATES. THE FASI NETWORK BRINGS TOGETHER CLINICAL EXPERTS IN FOOD ALLERGIES, TYPE 2 INFLAMMATORY DISORDERS, CHRONIC INFLAMMATORY DISEASES, AS WELL AS RESEARCH EXPERTS WITH DEEP EXPERTISE IN STUDYING THE IMMUNE SYSTEM, THE DIGESTIVE SYSTEM, THE NERVOUS SYSTEM, AND THE GUT MICROBIOME, ALL OF WHICH INTERSECT AND CONTRIBUTE TO THE UNDERLYING CAUSES OF FOOD ALLERGIES. THOUGH A COLLABORATIVE OPERATING MODEL, FASI'S TEAM OF RESEARCHERS ARE LASER FOCUSED ON UNDERSTANDING THE ROOT CAUSES OF FOOD ALLERGIES, TRANSLATING THESE FINDINGS FROM LABS TO CLINICS, AND BEGINNING TO INTERVENE THROUGH THE GENERATION OF NOVEL THERAPEUTIC CANDIDATES TO ONE DAY DELIVER A CURE TO THOSE AFFECTED BY FOOD ALLERGIES. SOME OF OUR ACHIEVEMENTS: -FASI'S SCIENTIFIC FOUNDER, RUSLAN MEDZHITOV, HAS BEEN VISIONARY IN DEVELOPING A CONCEPTUAL FRAMEWORK OF FOOD ALLERGY BY PROPOSING THAT THE ALLERGIC RESPONSE IS A HYPERACTIVE REACTION OF THE BODY'S FOOD QUALITY CONTROL SYSTEM - A PARADIGM SHIFT THAT HAS GUIDED FASI'S INTER-DISCIPLINARY COLLABORATIVE RESEARCH APPROACH. -FASI IS CREATING A DETAILED UNBIASED CELLULAR ATLAS COMPARING GUTS FROM FOOD ALLERGIC AND NON-ALLERGIC PATIENTS. BY EXAMINING DIFFERENCES THAT UNDERLIE DISEASE-RELEVANT HUMAN TISSUES, THIS ATLAS WILL HELP US - AND THE WIDER SCIENTIFIC COMMUNITY AS A WHOLE - IDENTIFY AND CHARACTERIZE WHICH CELLS-TYPES ARE EXPANDED AND DYSREGULATED IN FOOD ALLERGY PATHOLOGY, AND TO IDENTIFY PATHWAYS OF THERAPEUTIC INTERVENTION TO REVERSE PATHOLOGICAL DIFFERENCES. -FASI SCIENTISTS WERE AMONG THE FIRST TO IDENTIFY CRUCIAL LINKS BETWEEN THE GUT IMMUNE AND NERVOUS SYSTEMS BY IDENTIFYING SPECIFIC CELL-TYPES AND MOLECULAR MEDIATORS INVOLVED IN THE PROCESS OF ALLERGIC SENSITIZATION AND AUGMENTATION OF ALLERGIC IMMUNE RESPONSES. THESE CRITICAL INTERACTIONS SERVE AS DECISION CHECKPOINTS FOR HOW THE BODY DECIDES TO EITHER TRIGGER AN ALLERGIC REACTION OR MAINTAIN NORMAL PHYSIOLOGICAL FUNCTIONING. -FASI IS UNCOVERING PATHWAYS OF BI-DIRECTIONAL COMMUNICATIONS BETWEEN THE GUT AND THE BRAIN. THE BRAIN PERFORMS THE CRITICAL FUNCTION OF SENSING INTERNAL CHANGES WITH THE BODY AND ORCHESTRATING SYSTEMIC PHYSIOLOGICAL RESPONSES, INCLUDING MOBILIZING ENERGY RESERVES TO MEET METABOLIC DEMANDS, ACTIVATING IMMUNOLOGICAL RESOURCES TO DEFEND BARRIER SURFACES, MODIFYING BEHAVIORS AND FORMING MEMORIES FOR PRO-SURVIVAL ADAPTIVE PURPOSES. UNDERSTANDING THIS UNDEREXPLORED AREA PROMISES TO REVEAL NOVEL AVENUES FOR THERAPEUTIC INTERVENTIONS. -FASI RESEARCHERS ARE WORKING TO ELUCIDATE HOW ADJUVANTS - SUBSTANCES CAPABLE OF MAGNIFYING THE IMMUNE RESPONSE - ARE FOUND IN UNEXPECTED PLACES, INCLUDING THE FOODS WE CONSUME AND THE ENVIRONMENTS WE ARE EXPOSED TO, AND OUR RESEARCH SHOWS THAT THESE ADJUVANTS ARE CRITICAL CONTRIBUTORS TO THE DEVELOPMENT OF ALLERGIC DISEASES. THESE ADJUVANTS DERIVED FROM PLANTS, ANIMALS, OR STANDARD INDUSTRIAL PROCESSING PRACTICES, CAN BE FURTHER MODIFIED BY THE MICROBIOME IN OUR GUT, ARE SENSED BY SPECIALIZED CELLS THAT LINE THE GUT WALL, AND CAN SKEW THE IMMUNE RESPONSE TOWARD A HYPERALLERGIC STATE. -FASI SCIENTISTS ARE STUDYING FOOD ALLERGIC PATIENTS UNDERGOING INTERVENTIONAL TREATMENTS, SUCH AS ORAL IMMUNOTHERAPY (OIT), TO UNDERSTAND HOW IMMUNE RESPONSES ADAPT DURING THERAPEUTIC INTERVENTIONS. THROUGH DETAILED PROFILING OF INDIVIDUALS' IMMUNE RESPONSES, WE HAVE IDENTIFIED IMMUNOLOGICAL CHANGES THAT HELP EXPLAIN WHY OIT CAN INDUCE LONG-TERM DESENSITIZATION TO ALLERGENS, WHILE IS ONLY TRANSIENTLY PROTECTIVE IN OTHER INDIVIDUALS AFTER TREATMENT IS STOPPED. UNDERSTANDING THE IMMUNE MECHANISMS CONTRIBUTING TO THESE DIFFERING RESPONSES WILL GUIDE US TOWARD CRITICAL PATHWAYS LEADING TO LONG-TERM DESENSIZATION SUCCESS, AND ULTIMATELY A DISEASE-MODIFYING CURE. -FASI SCIENTISTS HAVE MADE BREAKTHOUGH CONNECTIONS IN UNDERSTANDING THE SKIN'S ROLE IN FOOD ALLERGIES, INCLUDING HOW THE SKIN CAN ACT AS A SITE OF INITIAL SENSITIZATION. FASI RESEARCHERS WERE THE FIRST TO IDENTIFY HOW SOME ALLERGENS ARE CAPABLE OF DIRECTLY ACTIVATING NERVES IN THE SKIN, WHICH CAN LEAD TO THE SENSATION OF ITCH, BUT ALSO THAT SKIN-INNERVATING NERVES CAN ACTIVATE IMMUNE CELLS AND DRIVE THEM TO INITIATE AN ALLERGIC RESPONSEY. THIS RESEARCH IS HELPING US UNDERSTAND HOW SKIN DISORDERS, SUCH AS ITCH AND ATOPIC DERMATITIS, ARE LINKED AND ARE OFTEN RISK FACTORS IN THE DEVELOPMENT OF FOOD ALLERGIES. BLOCKING THIS PATHWAY COULD BE AN IMPORTANT THERAPEUTIC STRATEGY TO PREVENT THE DEVELOPMENT OF FOOD ALLERGIES IN HIGH-RISK INDIVIDUALS. -FASI INVESTIGATORS COMPLETED IN-DEPTH ANALYSIS OF ANTIBODY-PRODUCING PLASMA CELLS FROM HUMAN BONE MARROW OF PEANUT-ALLERGIC INDIVIDUALS AND FOUND SOME PLASMA CELLS PRODUCING PATHOLOGICAL IGE ANTIBODIES THAT BOUND PEANUT. THIS WORK IDENTIFIED BONE MARROW AS A CRITICAL TISSUE RESERVOIR FOR PATHOGENIC IGE-PRODUCING PLASMA CELLS. -FASI HAS ESTABLISHED A DRUG DEVELOPMENT TEAM WITH DECADES OF PHARMA/BIOTECH EXPERIENCE ADVANCING SMALL MOLECULES AND LARGE BIOLOGICS FROM EARLY TARGET IDENTIFICATION STAGES INTO THE CLINIC. THIS TEAM IS WORKING TO BUILD CRITICAL TOOLS AND PARTNERSHIPS TO ADVANCE EXCITING NOVEL THERAPEUTIC CANDIDATES FOR THE DEVELOPMENT OF THE NEXT GENERATION OF FOOD ALLERGY TREATMENTS. -FASI'S INVESTIGATIONAL RESEARCH HAS LED TO 6 PATENTS, 100+ PUBLICATIONS AND OVER 6490+ CITATIONS IN THE MEDICAL LITERATURE. THROUGH FASI'S COLLABORATIVE, INTERDISCIPLINARY RESEARCH APPROACH, FASI'S TEAM OF SCIENTISTS AND DRUG DEVELOPERS HAVE BUILT A DYNAMIC DRUG DISCOVERY ENGINE TO IDENTIFY INNOVATIVE THERAPUTIC INTERVENTIONS, AND ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH DISCOVERIES TO TRANSFORM THE LIVES OF PATIENTS LIVING WITH FOOD ALLERGIES. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE ORGANIZATION'S FORM 990 IS PREPARED BY A REPUTABLE CPA FIRM SPECIALIZING IN NOT FOR PROFIT TAX. THE FORM 990 IS PROVIDED TO THE CEO FOR REVIEW AND COMMENT AND ANY CHANGES ARE INCORPORATED. THE ORGANIZATION PROVIDES A DRAFT COPY OF FORM 990 FOR THE BOARD TO REVIEW PRIOR TO FILING. UPON APPROVAL THE ORGANIZATION FILES ITS 990. |
| FORM 990, PART VI, SECTION B, LINE 12C | Each FASI Director, Advisor and staff member SIGNS A CONFLICT OF INTEREST FORM AND receives an annual reminder of Conflict of Interest Policy in January of each year. While reaffirmation of the Policy is not required, existing FASI Directors, Advisors and staff must notify the Executive Director and/or his/her delegate immediately of any change in status related to potential Conflict of Interest issues. In addition, FASI will conduct periodic reviews of arrangements and policies to ensure that FASI operates in a manner consistent with charitable purposes and does not engage in activities that could jeopardize its tax-exempt status. |
| FORM 990, PART VI, SECTION B, LINE 15: | COMPENSATION PROCESS FOR TOP OFFICIAL: THE ORGANIZATION USES THE DEPARTMENT OF LABOR STATISTICS AND SALARY GUIDE TO OBTAIN COMPARABLE DATA ON POSITIONS. FURTHERMORE, THE ORGANIZATION PERIODICALLY REVIEW THE COMPENSATION ARRANGEMENTS AND BENEFITS TO ENSURE THAT THEY ARE REASONABLE, BASED ON COMPETENT SURVEY INFORMATION AND THE RESULT OF ARM'S LENGTH BARGAINING. |
| FORM 990, PART VI, SECTION C, LINE 19 | GOVERNING DOCUMENTS, DISCLOSURE EXPLANATION, THE FINANCIAL STATEMENTS, AND OTHER DOCUMENTS, SUCH AS THE CONFLICT OF INTEREST POLICY AND GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. |
| FORM 990, PART XI, LINE 9: | Grants refunded $ 356,671 |
| Software ID: | |
| Software Version: |